| pubmed-article:15205945 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15205945 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:15205945 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:15205945 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
| pubmed-article:15205945 | lifeskim:mentions | umls-concept:C0574032 | lld:lifeskim |
| pubmed-article:15205945 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:15205945 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:15205945 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:15205945 | pubmed:dateCreated | 2004-7-16 | lld:pubmed |
| pubmed-article:15205945 | pubmed:abstractText | The best way to deliver infusional 5-fluorouracil (5-FU) and folinic acid (FA) has yet to be determined. The aim of this prospective phase II trial was to verify the tolerability, activity and efficacy of chronomodulated 5-FU-FA (FF(5-16)) every 3 weeks in 48 untreated patients (group A), and 28 pretreated and four non-measurable, advanced colorectal cancer (ACC) patients (group B). | lld:pubmed |
| pubmed-article:15205945 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15205945 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15205945 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15205945 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15205945 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15205945 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15205945 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:15205945 | pubmed:issn | 0171-5216 | lld:pubmed |
| pubmed-article:15205945 | pubmed:author | pubmed-author:GiannarelliDi... | lld:pubmed |
| pubmed-article:15205945 | pubmed:author | pubmed-author:TerzoliEdmond... | lld:pubmed |
| pubmed-article:15205945 | pubmed:author | pubmed-author:GarufiCarloC | lld:pubmed |
| pubmed-article:15205945 | pubmed:author | pubmed-author:CappelliniGia... | lld:pubmed |
| pubmed-article:15205945 | pubmed:author | pubmed-author:VanniBarbaraB | lld:pubmed |
| pubmed-article:15205945 | pubmed:author | pubmed-author:ZappalàAlbina... | lld:pubmed |
| pubmed-article:15205945 | pubmed:author | pubmed-author:PugliesePatri... | lld:pubmed |
| pubmed-article:15205945 | pubmed:author | pubmed-author:AschelterAnna... | lld:pubmed |
| pubmed-article:15205945 | pubmed:author | pubmed-author:PerroneMariaM | lld:pubmed |
| pubmed-article:15205945 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15205945 | pubmed:volume | 130 | lld:pubmed |
| pubmed-article:15205945 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15205945 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15205945 | pubmed:pagination | 445-52 | lld:pubmed |
| pubmed-article:15205945 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:meshHeading | pubmed-meshheading:15205945... | lld:pubmed |
| pubmed-article:15205945 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15205945 | pubmed:articleTitle | High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients. | lld:pubmed |
| pubmed-article:15205945 | pubmed:affiliation | SC Oncologia Medica C, Istituto Regina Elena, Istituti Fisioterapici Ospitalieri, Via E. Chianesi, 53, 00144 Rome, Italy. garufi@ifo.it | lld:pubmed |
| pubmed-article:15205945 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15205945 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15205945 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
